Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire Phadia, a global leader in allergy and autoimmunity diagnostics, from European private equity firm Cinven, for €2.47 billion in cash.
Thermo Fisher Scientific to acquire Phadia for €2.47 billion